Aquestive is the undisputed leader in developing and delivering medications via film through our PharmFilm technology. Building on our success, we now have a robust CNS and complex molecule portfolio. We continuously strive to identify therapeutic areas where our proprietary technologies can help improve patient outcomes.
| Program | Molecule | Indication | Formulation | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Filed | Marketed |
|---|---|---|---|---|---|---|---|---|---|
| CNS Programs | |||||||||
| AQST-120 (Sympazan™) | clobazam | Lennox-Gastaut syndrome | |||||||
| AQST-203 | diazepam* | Acute Repetitive Seizures | |||||||
| AQST-117 | riluzole* | ALS | |||||||
| Complex Molecule Programs | |||||||||
| AQST-108 | epinephrine* | Anaphylaxis | |||||||
| AQST-305 | octreotide* | Acromegaly / Carcinoid Syndrome | |||||||
| Partnered Programs | |||||||||
| Suboxone (Partner: Indivior) | buprenorphine / naloxone | Opioid Dependence | |||||||
| Zuplenz (Partner: Midatech) | ondansetron | CINV / PINV | |||||||
| APL-130277 (Partner: Sunovion) | apomorphine* | Parkinson’s Disease | |||||||
| AQST-119 | tadalafil* | Erectile Dysfunction / BPH | |||||||
*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.
Current as of October 2018
CNS Programs
AQST-120
+
–
Molecule: clobazam
Indication: Lennox-Gestaut syndrome
Phase: filed
AQST-203
+
–
Molecule: diazepam*
Indication: acute repetitive seizures
Phase: 3
AQST-117
+
–
Molecule: riluzole*
Indication: ALS
Phase: 3
Complex Molecule Programs
AQST-108
+
–
Molecule: epinephrine*
Indication: Anaphalaxis
Phase: 1
AQST-305
+
–
Molecule: octreotide*
Indication: Acromegaly / Carcinoid Syndrome
Phase: 1
Partnered Programs
Suboxone
+
–
Molecule: buprenorphine / naloxone
Indication: Opioid Dependence
Phase: marketed
Partner: Indivior
Zuplenz
+
–
Molecule: ondansetron
Indication: CINV / PINV
Phase: filed
Partner: Midatech
APL-130277
+
–
Molecule: apomorphine*
Indication: Parkinson’s Disease
Phase: 3
Partner: Sunovion
AQST-119
+
–
Molecule: tadalafil*
Indication: Erectile Dysfunction / BPH
Phase: filed
Partner: Actively pursuing partnerships
*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.
Current as of October 2018
NOW APPROVED
The first and only FDA approved film formulation of clobazam.
Click here to learn more Please see full prescribing information, including BOXED WARNING
Latest comments
Sorry, the comment form is closed at this time.